13.2 C
London
Tuesday, November 17, 2026

Hope for new low cost slimming pill as new drug is trialled

A new oral medication could help patients lose more weight than by taking the active ingredient used in the new Wegovy weight loss pills, a promising study has found.

The drug, called orforglipron, is a GLP-1 agonist and targets the same appetite receptors as fat jabs such as Mounjaro, Wegovy and Ozempic, but is taken in tablet form rather than administered via injection.

Orforglipron has been developed to treat both type 2 diabetes and obesity, and  as part of a trial by its manufacturer Eli Lily, was compared to an existing medication, oral semaglutide, sold under the brand name Rybelsus.

Rybelsus and the Wegovy Pill – which launched in the US in January and NHS chiefs hope to roll out in the UK by the end of this year – are the same medication, manufactured by Novo Norsk, but the former is approved for the treatment of type 2 diabetes and the latter for weight loss. 

In a trial of over 1,500 patients from Argentina, China, Japan Mexico and the US, patients who took orforglipron for a year experienced a greater drop in blood sugar levels and lost more weight than those on semaglutide.

In the study, 1,698 participants were randomly assigned to receive either orforglipron, at a dose of 12mg or 36mg, or oral semaglutide, at 7mg or 14mg.

Participants took their medication every day for a year, starting on a lower dose and increasing every four weeks until reaching their randomly assigned dose.

Results showed that both doses of orforglipron were better than that of semaglutide in reducing blood glucose levels, and they also lost more weight.

The new drug was tested against the diabetes treatment version of the Wegovy pill

Patients with type 2 diabetes are recommended to lose between 5-15 per cent body weight to help manage their condition, with a more than 10 per cent reduction having disease-modifying effects including potential remission.

Up to 43 per cent of participants on orforglipron were able to drop at least 10 per cent body weight, while only 21 per cent of those on semaglutide dropped enough weight to slash their risk of heart complications.

However, the weight loss seen among people taking orforglipron was not as extreme as results seen in patients taking Mounjaro, which contains the active ingredient tirzepatide.

Orforglipron can also be taken with food, making it much more convenient than semaglutide, which needs to be taken on an empty stomach. Experts have already stated that they believe GLP-1 tablets will be more accessible than injections – and potentially in the future, more affordable due to different packaging, storage and shipment requirements.

Writing in medical journal The Lancet, the authors said: ‘Our results suggest that orforglipron represents an important advancement in the oral treatment landscape for type2 diabetes.

‘It’s efficacy, safety, tolerability, and simple doing could address important barriers associated with current therapies, offering a new highly efficacious and safe option for individuals seeking glycemic and weight control with the use of injections.’

The researchers noted the difference in blood sugar control was already significant after just a month of treatment and was sustained until the end of the trial.

The results were particularly strong for patients with higher blood sugar levels at the start of the trial.

Around a quarter of patients taking orforglipron managed to reach near-normal blood sugar levels during the course of the study whilst only around 12 per cent of those on semaglutide managed to reduce their blood sugar to safe levels.

If approved, orforglipron (which like Mounjaro, is manufactured by Eli Lily) could become the next GLP-1 drug approved for weight management.

Weight loss jabs have transformed obesity treatment, offering dramatic weight loss that was largely out of reach with diet and exercise alone.

Two in three Britons are now overweight or obese, driving a nearly 40 per cent rise in type 2 diabetes among under 40s.

The researchers concluded: ‘Orforglipron represents meaningful improvements in glycemic control and weight reduction compared with oral semaglutide in patients with type 2 diabetes, and with larger improvements in cardiometabolic risk factors and simplified administration.’

However, during the course of the study around 10 per cent of participants on orforglipron had to stop taking the pill due to adverse reactions, such as gastrointestinal issues.

Only 5 per cent of patients taking semaglutide experienced similar adverse reactions.

 

Hot this week

Timothee Chalamet matches Kylie Jenner in another cringe look

Just a day after the reality TV star, 28, was pictured in a red latex dress in West Hollywood, the Dune actor, 29, stepped out in an all-red leather look while out in New York on Monday.

Jimmy Kimmel gives sorry excuse for Melania ‘widow’ joke

Jimmy Kimmel joked about Donald Trump and Melania Trump's calls for him to be fired before reacting to the shooting attempt at the White House Correspondents' Dinner.

Woman who married illegal migrant she met in Australia is rescued after he took her to Pakistan, ‘kept her prisoner and beat her every...

French national Sylvie Yasmina, 54, agreed to move to Pakistan with her husband - but claims she was then put through more than a decade of hell.

Trump smiles and fist pumps as he’s greeted by 300 chanting kids

Trump has touched down in Beijing , kicking off a three-day visit marking the first time a sitting US President has visited China in roughly nine years.

Actress said to have sparked Brigitte’s infamous ‘slap’ of Emmanuel

Brigitte Macron's slap of her husband Emmanuel was sparked when she saw a message on his phone from Iranian actress Golshifteh Farahani, a new book has claimed.

‘There is a hijacking. We have taken control of the terrorist – we need help’: Passenger films plea for assistance moments after overpowering knifeman...

The hero who helped subdue the knifeman is seen in footage with blood dripping down his face, emerging from a gash that stretches from his forehead down to his nose.

Dakota Johnson appears to run out of patience and says ‘I’m gonna leave’ as Anne Hathaway takes charge and directs photographers on Verity red...

They've spoken about their close bond saying they had 'great chemistry as friends on the set' of their new movie Verity. 

Katie Holmes, 47, and boyfriend Jason Bard Yarmosky, 39, enjoy another romantic getaway in Lake Como before jetting to Paris Fashion Week

The actress, 47, has been showcasing her romance with the artist, 39, during this year's catwalk season, but flew to the luxurious hotspot for a romantic getaway.

How will the triple lock change from 2030 and what do Andy Burnham’s plans mean for you?

We examine what the state pension is, how it currently works and increases, what is changing and why and how the changes will affect people's finances.

Failed asylum seeker who called for death to Jews and praised Hamas is moved by police after he was found living in taxpayer-funded semi

Palestinian migrant Abu Wadee, 34, served nine months in prison after he was exposed by the Mail on Sunday as arriving in the UK in a small boat in March 2025.

Giggling Kate delights elderly minibus passengers as she joins volunteers community group that helps pensioners enjoy their independence

Catherine arrived in picturesque Pulborough to join the team at the West Sussex Minibus, which acts as a vital lifeline for people who cannot easily access public transport.

Tom Cruise fawns over ‘stunning’ Kate Middleton and says the future king made a ‘smart choice’ marrying her because she is ‘intelligent, charismatic and...

Tom Cruise couldn't hide his delight over his recent meeting with Kate Middleton as he gushed over the 'stunning' Princess Of Wales in a new interview.

How will the triple lock change from 2030 and what do Andy Burnham’s plans mean for you?

We examine what the state pension is, how it currently works and increases, what is changing and why and how the changes will affect people's finances.
spot_img

Related Articles

Popular Categories

spot_imgspot_img